Prescient’s clinical trial goes from strength to strength, with recruitment expanded for its PTX-100 cancer study
Strong early indicators for the PTX-100 treatment give Prescient multiple pathways to market, as it...
Strong early indicators for the PTX-100 treatment give Prescient multiple pathways to market, as it...
Investors have plenty of exciting updates to look forward as PTX advances clinical trials and...
Is the leukemia busting CAR-T cell therapy, championed by Aussie-listed Prescient, the holy grail of...
With around $15m in the bank, Prescient is pressing ahead to move its novel OmniCAR...
Prescient’s OmniCAR platform could overcome the limitations of CAR-T treatments for cancer and it’s attracting...
Stockhead’s resident health and biotech expert Tim Boreham is putting down the microscope and picking up...
The appointment gives PTX a world-leading development team in the race to find solutions for...
Got 90 seconds? Then listen to CEO, Steven Yatomi-Clarke tell us about their company news....
Prescient Therapeutics (ASX:PTX) says its cancer-fighting drug candidate has exhibited an excellent safety in an...
The results significantly de-risk the project as PTX continues development of its OmniCAR platform. As...

This investor centre was built by Reach Markets
©2026 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.